JPM2025 Kicks Off with Record-Breaking $100B+ in M&A Deals as Lilly, Novartis, GSK Unveil Major Transactions

This Monday,Johnson & Johnson Announces $14.6 Billion Acquisition of Intra-Cellular Therapeutics, Focused on CNS Disorder Treatments`, can be called`"First Major Acquisition of the Year", which is also the highest amount of M&A transaction in the biotech sector in the past two years. This company owns a core psychiatric treatment drug called Caplyta. Johnson & Johnson believes that this drug has the potential to become a benchmark for the treatment of schizophrenia, bipolar disorder, and major depressive disorder, with future annual...Peak sales will exceed $5 billion.。

In addition,Eli Lilly and CompanyAt the highest$2.5 billionThe cash acquisition of Scorpion Therapeutics' experimental cancer therapy;GlaxoSmithKline PLC.(GSK) will pay up to$1.15 billionAcquisition of Biotech Company IDRx;GileadIn$1.7 billionThe total transaction volume introduced a preclinical STAT6 inhibitor from LEO Pharma;BiogenClearly stated that it will continue to expand its strength through mergers and acquisitions in 2025… The trading boom at JPM is surging, far exceeding last year's scale.

The heavy investment by pharmaceutical giants may be related to their own external needs. Shreeram Aradhye, Chief Medical Officer of Novartis, once mentioned, "Due to pressures such as the drug price negotiation provisions in the Inflation Reduction Act,Large pharmaceutical companies are in greater need of external innovation than ever before.." At the same time, many senior executives also pointed out that "large pharmaceutical companies are facing the issue of upcoming patent expirations, so they are under pressure to make deals."

The acquisition activities of these pharmaceutical giants are of great significance in promoting the development of the healthcare field. The acquirer and the acquired can complement each other's strengths, optimize the global market layout of drugs, increase market share, promote technological integration and innovation, and help diversify the reliance of pharmaceutical giants on a single product or market, enhancing their risk resistance capability. Overall, it will have a positive impact on the industry.It may also lead to a new round of reshuffling.。

These deals have also led to a shift in sentiment among industry insiders regarding the biotech sector's outlook for 2025. Julia Owens, a CEO of a biotech company with 25 years of industry experience, believes the sector is returning to a "healthy normalcy." She stated, "I'm optimistic about this year, but I hope we can rebuild in a healthy, incremental way rather than giving the impression that we've returned to the days filled with bubbles. I think we need...Focus on Patients, Focus on Science。”

Following an "explosive" start marked by a series of multi-billion-dollar deals, the JPM conference continues with high intensity, as several large pharmaceutical companies have announced new developments.

Lilly: Full-year revenue of approximately $45 billion in 2024, with strong overall growth

Eli Lilly and Company revealed its 2024 sales performance overview at this year's JPM conference——Global revenue is approximately US$45 billion, representing a 32% increase compared to 2023. Its global revenue in the fourth quarter was approximately $13.5 billion, slightly below the analysts' consensus expectation of $13.9 billion.

In this regard, CEO David Ricks believes that,"Lower-than-expected channel inventory at the end of the year" and overestimation of the accelerated development of the U.S. GLP-1 market were the reasons for the fourth quarter's underperformance.However, overall, Eli Lilly is optimistic about its future revenue expectations, with projected sales for 2025 expected to be between $58 billion and $61 billion.

Lilly believes there are still many growth avenues in the GLP-1 market, including the expansion of new indications and the development of new markets.At the same time, beyond diabetes and weight loss products, Eli Lilly also has several new drugs, such as Kisunla for Alzheimer's disease, Omvoh for ulcerative colitis, and Ebglyss for atopic dermatitis.

On January 15 this year, Eli Lilly announced that the U.S. FDA had approved its drug Omvoh for the treatment of moderate to severe active Crohn's disease (CD) in adults. This product was previously listed as one of the top 10 potential blockbuster therapies. Notably, Omvoh is the first biologic therapy in 15 years to publicly disclose two-year Phase 3 Crohn's disease efficacy data at the time of approval. Research data shows that among patients who achieved clinical remission and endoscopic remission in the first year,Nearly 90% of patients maintained clinical remission after one year.。This also provides new momentum for its future sales growth.

Novartis: Focus on Core Business After Spin-off, Continuously Drive Performance Growth

According to Novartis CEO Vas Narasimhan, after completing the spin-offs of Alcon and Sandoz, Novartis successfully transformed into a company focused on innovative medicines, concentrating on four core disease areas: cardiovascular, renal, and metabolic diseases; immunology; neuroscience; and oncology, building a comprehensive portfolio.Biotechnology, Chemical Pharmaceuticals, xRNA Technology, Radioligand Therapy, and Gene and Cell TherapyThe five major technology platforms.

Novartis' performance has maintained strong growth in recent years, bringing robust cash flow and a solid return on investment, with 13 "blockbuster" drugs in its portfolio. Vas Narasimhan believes that Kisqali, for breast cancer, will become one of Novartis' best-selling drugs ever, with peak sales potentially exceeding$8 billion, which occupies more than half of the U.S. early-stage breast cancer market share.

RDC drug Pluvicto is also one of the future growth points for Novartis' performance., its sales peak will exceed$5 billion, and the radiopharmaceuticals track has also become one of the most heated fields in recent years. Novartis, with two marketed products (Lutathera and Pluvicto) and multiple pipelines in development, is already one of the leading players in this field, showcasing the sales potential of radiopharmaceuticals. Additionally, there are products like Scemblix, Kesimpta, and Entresto, each with annual sales potentially reaching several billion dollars.

GSK: Focus on Specialty Medicines and Vaccines, Drive Approval of 5 Products

GSK said it is expectedFull-year 2024 sales are expected to achieve growth of 7% to 9%, with operating profit growth projected to reach 11% to 13%.Looking ahead to 2025, GSK's biggest focus will be on its plan to push for the approval of five products, further enhancing its momentum for future performance growth.

These five products specifically include: BCMA ADC drug Blenrep, long-acting IL-5 antibody Depemokimab, Nucala for chronic obstructive pulmonary disease (COPD), novel oral antibiotic Gepotidacin, and pentavalent meningococcal vaccine MenABCWY.

Among them, ADC drugsBlenrepPreviously approved via the FDA's accelerated approval pathway in 2020 as a monotherapy for the treatment of R/R MM patients, but later initiated withdrawal procedures in the U.S. due to the results of the Phase 3 DREAMM-3 clinical trial. In 2024, positive results were reported from the Phase 3 clinical trials DREAMM-7 and DREAMM-8 for Blenrep combination therapy, and GSK has submitted its marketing applications in multiple countries. GSK forecasts the drug’s peak sales to reach£3 billion。

AstraZeneca: 9-Month Revenue of $39.2 Billion, Aiming for $80 Billion Revenue

AstraZeneca mainly focuses on five core therapeutic areas: oncology, cardiovascular, renal and metabolic diseases (CVRM), respiratory and immunology (R&I), vaccines and immune therapies (V&I), and rare diseases. In the first three quarters of 2024,These five areas have contributed revenue of $39.2 billion, increasing 19% from the same period last year.。

ADC, radiopharmaceutical conjugates, next-generation IO bispecific antibodies, cell therapy and T-cell engagers, gene therapy and gene editing will be the key细分赛道that AstraZeneca focuses on, and significant progress has already been made. By the end of 2024, AstraZeneca will have 91 late-stage R&D pipelines ongoing, and in the future these...PipelineThe average annual revenue peak is expected to exceed 1 billion US dollars. Additionally, AstraZeneca stated that within 5 years, it aims to successfully launch at least 20 New Molecular Entities (NMEs) into the market, helping the company achieve$80 billionThe revenue target.

Gilead: Revenue Reversal Trend, to Launch CAR-T Cell Therapy in 2026

After two consecutive years of declining performance, Gilead stabilized and rebounded in 2024, with expectations to continuously expand its revenue scale. This trend reversal is considered to be a result of "past investments translating into commercial benefits." It is reported that Gilead currently owns more than100 ItemsThe innovative Pre-IND and clinical trial programs boast a very large pipeline, covering a broad range of fields.

Gilead specifically mentioned its HIV new drug development plan,Nine products targeting HIV are expected to be launched before 2033.In order to offset the impact of the sales decline of Biktarvy after the loss of market exclusivity, lenacapavir, Gilead’s core product in the HIV field, has drawn significant attention. Its efficacy in HIV pre-exposure prophylaxis (PrEP) reaches 100%, with only two doses required per year. This indication is expected to be approved in 2025, bringing a new growth point for the company.

It is worth noting that,Gilead Expected to Launch CAR-T Cell Therapy Anito-cel in 2026, This is a BCMA CAR-T jointly developed with Arcellx, targeting relapsed or refractory multiple myeloma, and it is already in Phase 3 clinical trials. The BCMA-binding segment of Anito-cel uses the D-domain, which is only 8kDa, offering high transfection efficiency and better stability. Previously published research results show that patients receiving Anito-cel treatment haveOverall Response Rate (ORR) reached 100%, with Complete Response/Stringent Complete Response (CR/sCR) rate approaching 80%., and it has a good safety profile.

In addition, many well-known companies announced new developments at the 2025 JPM conference, which will not be listed one by one in this article. Overall, at the 2025 JPM conference, the giants of the global pharmaceutical industry demonstrated their ambitions and forward-looking strategies, injecting new vitality and hope into the development of the biopharmaceutical industry.

JPM Conference, as an Important Barometer and Communication Platform for the Global Pharmaceutical Industry, Offers Reference for Future Development While Providing a Bridge for Transactions and Cooperation Among Participating Companies. In the Future, with Continuous Changes in the Global Biomedical Market and Increasing Competition, Enterprises Will Place Greater Emphasis on Strategic Collaboration and Resource Integration. It Is Predictable That the Biomedical Sector Will Reach New Heights.

Here, the editor has collected 81 presentation materials from participating pharmaceutical companies at JPM2025 for industry reference. You can add 医麦客-大海 as a WeChat friend and send the keyword "Corning" to gain access to the download.

References:

1.https://www.biospace.com/deals/biopharma-deals-start-flowing-at-jpm25-with-one-dwarfing-last-years-activity

2. Public materials such as JPMorgan's official website

3. All images in the article are sourced from PPTs released by individual companies.

Dian Dian "Share”、“Like" and "In View", charge me up a bit~"